대한의생명과학회지 (Biomedical Science Letters)

  • 제24권3호
  • /
  • Pages.168-174
  • /
  • 2018
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

The Improving Effect of Gastrodia elata Blume on DSS-induced Colitis in Mice

  • Ahn, Eun-Mi (Department of Biotechnology and Convergence, DaeguHanny University) ;
  • Kim, Su-Jin (Department of Biotechnology and Convergence, DaeguHanny University)
  • 투고 : 2018.04.16
  • 심사 : 2018.09.13
  • 발행 : 2018.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, rectal bleeding and diarrhea. Gastrodia elata Blume (GE) has been used for the treatment of various diseases including neurodegenerative diseases and inflammatory disease. However, there has been no information on whether GE regulates intestinal inflammation. The aim of this study is to elucidate whether GE can protect against dextran sulfate sodium (DSS)-induced colitis in a mouse model. The colitis mice were induced by drinking water containing 5% DSS for 7 days. Body weight, colon length and clinical score were assessed to determine the effects on colitis. The levels of inflammatory cytokines, tumor necrosis factor $(TNF)-{\alpha}$ and interleukin (IL)-6 in colitis tissue were also measured. The results showed that mice administrated with DSS showed clinical signs including weight loss and reduced colon length. GE inhibited the DSS-induced loss of body weight and shortening of colon and increased Disease activity index score. Additionally, we observed that GE suppressed the levels of $TNF-{\alpha}$ and IL-6 in DSS-treated colon tissues. Collectively, these findings provide experimental evidence that GE might be a useful therapeutic agent for patients with UC.

키워드

참고문헌

  1. Ardizzone S, Bianchi PG. Biologic therapy for inflammatory bowel disease. Drugs. 2005. 65: 2253-2286. https://doi.org/10.2165/00003495-200565160-00002
  2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nature Reviews Immunology. 2003. 3: 521-533. https://doi.org/10.1038/nri1132
  3. Camuesco D, Galvez J, Nieto A, Comalada M, Rodriguez-Cabezas ME, Concha A, Xaus J, Zarzuelo A. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. The Journal of Nutrition. 2005. 135: 687-694. https://doi.org/10.1093/jn/135.4.687
  4. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation. 1993. 69: 238-249.
  5. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Reviews. 2004. 3: 394-400. https://doi.org/10.1016/j.autrev.2004.03.002
  6. Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion. 2006. 73: 67-76. https://doi.org/10.1159/000089781
  7. Eichele DD, Kharbanda KK. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World Journal of Gastroenterology. 2017. 23: 6016-6029. https://doi.org/10.3748/wjg.v23.i33.6016
  8. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998. 115: 182-205. https://doi.org/10.1016/S0016-5085(98)70381-6
  9. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and Pathophysiology of inflammatory bowel disease. Clinical Microbiology Reviews. 2002. 15: 79-94. https://doi.org/10.1128/CMR.15.1.79-94.2002
  10. Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and review: recent advances in the immunotherapy of inflammation bowel disease. Journal of Gastroenterology. 2003. 38: 36-42.
  11. Hyams JS. Inflammatory bowel disease. Pediatrics in Review. 2000. 21: 291-295. https://doi.org/10.1542/pir.21-9-291
  12. Ishiguro K, Ando T, Maeda O, Hasegawa M, Kadomatsu K, Ohmiya N, Niwa Y, Xavier R, Goto H. Paeonolattenuates TNBS-induced colitis by inhibiting $NF-{\kappa}B$ and STAT1 transactivation. Toxicology and Applied Pharmacology. 2006. 217: 35-42. https://doi.org/10.1016/j.taap.2006.07.002
  13. Kim SJ, Kim MC, Um JY, Hong SH. The beneficial effect of vanillic acid on ulcerative colitis. Molecules. 2010. 15: 7208-7217. https://doi.org/10.3390/molecules15107208
  14. Kim NH, Xin MJ, Cha JY, Ji SJ, Kwon SU, Jee HK, Park MR, Park YS, Kim CT, Kim DK, Lee YM. Antitumor and Immunomodulatory Effect of Gastrodia elata on Colon Cancer In vitro and In vivo. American Journal of Chinese Medicine. 2017. 45: 319-335. https://doi.org/10.1142/S0192415X17500203
  15. Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude J. Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010. 59: 227-235. https://doi.org/10.1136/gut.2009.184176
  16. Lin TY, Liu YC, Jheng JR, Tsai HP, Jan JT, Wong WR, Horng JT. Anti-enterovirus 71 activity screening of Chinese herbs with anti-infection and inflammation activities. The American Journal of Chinese Medicine. 2009. 37: 143-158. https://doi.org/10.1142/S0192415X09006734
  17. Matias M, Silvestre S, Falcao A, Alves G. Gastrodia elata and epilepsy: rationale and therapeutic potential. Phytomedicine. 2016. 23: 1511-1526. https://doi.org/10.1016/j.phymed.2016.09.001
  18. Murthy SN, Cooper HS, Shim H, Shah RS, Ibarahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Digestive Diseases and Sciences. 1993. 38: 1722-1734. https://doi.org/10.1007/BF01303184
  19. Neurath MF. Cytokines in inflammatory bowel disease. Nature. 2014. 14: 329-342.
  20. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. Journal of Clinical Immunology. 2007. 27: 275-283. https://doi.org/10.1007/s10875-007-9074-2
  21. Rokutan K, Kawahara T, Kuwano Y, Tominaga K, Nishida K, Teshima-Kondo S. Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Seminars in Immunopathology. 2008. 30: 315-327. https://doi.org/10.1007/s00281-008-0124-5
  22. Sandborn, WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002. 122: 1592-1608. https://doi.org/10.1053/gast.2002.33426
  23. Talhouk RS, Karam C, Fostok S, El-Jouni W, Barbour EK. Anti-inflammatory bioactivities in plant extracts. Journal of Medicinal Food. 2007. 10: 1-10. https://doi.org/10.1089/jmf.2005.055
  24. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Natrue Protocols. 2017. 12: 1295-1309. https://doi.org/10.1038/nprot.2017.044
  25. Yang SK. Current status and clinical characteristics of inflammatory bowel disease in Korea. The Korean Journal of Gastroenterology. 2002. 40: 1-14.
  26. Zhan HD, Zhou HY, Sui YP, Du XL, Wang WH, Dai L, Sui F, Huo HR, Jiang TL. The rhizome of Gastrodia elata Blume - an ethnopharmacological review. Journal of Ethnopharmacology. 2016. 189: 361-385. https://doi.org/10.1016/j.jep.2016.06.057
  27. Zheng P, Niu F, Liu W, Shi Y, Lu L. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitisofrats. World Journal of Gastroenterology. 2005. 11: 4912-4915. https://doi.org/10.3748/wjg.v11.i31.4912